Cargando…
GlyPerA™ effectively shields airway epithelia from SARS-CoV-2 infection and inflammatory events
New SARS-CoV-2 variants of concern (VOCs) and waning immunity illustrate that quick and easy-to-use agents are needed to prevent infection. To protect from viral transmission and subsequent inflammatory reactions, we applied GlyperA™, a novel antimicrobial formulation that can be used as mouth gargl...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10032620/ https://www.ncbi.nlm.nih.gov/pubmed/36949547 http://dx.doi.org/10.1186/s12931-023-02397-3 |
_version_ | 1784910842202947584 |
---|---|
author | Zaderer, Viktoria Dichtl, Stefanie Posch, Wilfried Abiatari, Ivane Bonn, Günther K. Jakschitz, Thomas Huber, Lukas A. Kurzchalia, Teymuras V. Wilflingseder, Doris |
author_facet | Zaderer, Viktoria Dichtl, Stefanie Posch, Wilfried Abiatari, Ivane Bonn, Günther K. Jakschitz, Thomas Huber, Lukas A. Kurzchalia, Teymuras V. Wilflingseder, Doris |
author_sort | Zaderer, Viktoria |
collection | PubMed |
description | New SARS-CoV-2 variants of concern (VOCs) and waning immunity illustrate that quick and easy-to-use agents are needed to prevent infection. To protect from viral transmission and subsequent inflammatory reactions, we applied GlyperA™, a novel antimicrobial formulation that can be used as mouth gargling solution or as nasal spray, to highly differentiated human airway epithelia prior infection with Omicron VOCs BA.1 and BA.2. This formulation fully protected polarized human epithelium cultured in air–liquid interphase (ALI) from SARS-CoV-2-mediated tissue destruction and infection upon single application up to two days post infection. Moreover, inflammatory reactions induced by the Omicron VOCs were significantly lowered in tissue equivalents either pre-treated with the GlyperA™ solution, or even when added simultaneously. Thus, the GlyperA™ formulation significantly shielded epithelial integrity, successfully blocked infection with Omicron and release of viral particles, and decreased intracellular complement C3 activation within human airway epithelial cell cultures. Crucially, our in vitro data imply that GlyperA™ may be a simple tool to prevent from SARS-CoV-2 infection independent on the circulating variant via both, mouth and nose. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-023-02397-3. |
format | Online Article Text |
id | pubmed-10032620 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-100326202023-03-23 GlyPerA™ effectively shields airway epithelia from SARS-CoV-2 infection and inflammatory events Zaderer, Viktoria Dichtl, Stefanie Posch, Wilfried Abiatari, Ivane Bonn, Günther K. Jakschitz, Thomas Huber, Lukas A. Kurzchalia, Teymuras V. Wilflingseder, Doris Respir Res Correspondence New SARS-CoV-2 variants of concern (VOCs) and waning immunity illustrate that quick and easy-to-use agents are needed to prevent infection. To protect from viral transmission and subsequent inflammatory reactions, we applied GlyperA™, a novel antimicrobial formulation that can be used as mouth gargling solution or as nasal spray, to highly differentiated human airway epithelia prior infection with Omicron VOCs BA.1 and BA.2. This formulation fully protected polarized human epithelium cultured in air–liquid interphase (ALI) from SARS-CoV-2-mediated tissue destruction and infection upon single application up to two days post infection. Moreover, inflammatory reactions induced by the Omicron VOCs were significantly lowered in tissue equivalents either pre-treated with the GlyperA™ solution, or even when added simultaneously. Thus, the GlyperA™ formulation significantly shielded epithelial integrity, successfully blocked infection with Omicron and release of viral particles, and decreased intracellular complement C3 activation within human airway epithelial cell cultures. Crucially, our in vitro data imply that GlyperA™ may be a simple tool to prevent from SARS-CoV-2 infection independent on the circulating variant via both, mouth and nose. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-023-02397-3. BioMed Central 2023-03-22 2023 /pmc/articles/PMC10032620/ /pubmed/36949547 http://dx.doi.org/10.1186/s12931-023-02397-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Correspondence Zaderer, Viktoria Dichtl, Stefanie Posch, Wilfried Abiatari, Ivane Bonn, Günther K. Jakschitz, Thomas Huber, Lukas A. Kurzchalia, Teymuras V. Wilflingseder, Doris GlyPerA™ effectively shields airway epithelia from SARS-CoV-2 infection and inflammatory events |
title | GlyPerA™ effectively shields airway epithelia from SARS-CoV-2 infection and inflammatory events |
title_full | GlyPerA™ effectively shields airway epithelia from SARS-CoV-2 infection and inflammatory events |
title_fullStr | GlyPerA™ effectively shields airway epithelia from SARS-CoV-2 infection and inflammatory events |
title_full_unstemmed | GlyPerA™ effectively shields airway epithelia from SARS-CoV-2 infection and inflammatory events |
title_short | GlyPerA™ effectively shields airway epithelia from SARS-CoV-2 infection and inflammatory events |
title_sort | glypera™ effectively shields airway epithelia from sars-cov-2 infection and inflammatory events |
topic | Correspondence |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10032620/ https://www.ncbi.nlm.nih.gov/pubmed/36949547 http://dx.doi.org/10.1186/s12931-023-02397-3 |
work_keys_str_mv | AT zadererviktoria glyperaeffectivelyshieldsairwayepitheliafromsarscov2infectionandinflammatoryevents AT dichtlstefanie glyperaeffectivelyshieldsairwayepitheliafromsarscov2infectionandinflammatoryevents AT poschwilfried glyperaeffectivelyshieldsairwayepitheliafromsarscov2infectionandinflammatoryevents AT abiatariivane glyperaeffectivelyshieldsairwayepitheliafromsarscov2infectionandinflammatoryevents AT bonnguntherk glyperaeffectivelyshieldsairwayepitheliafromsarscov2infectionandinflammatoryevents AT jakschitzthomas glyperaeffectivelyshieldsairwayepitheliafromsarscov2infectionandinflammatoryevents AT huberlukasa glyperaeffectivelyshieldsairwayepitheliafromsarscov2infectionandinflammatoryevents AT kurzchaliateymurasv glyperaeffectivelyshieldsairwayepitheliafromsarscov2infectionandinflammatoryevents AT wilflingsederdoris glyperaeffectivelyshieldsairwayepitheliafromsarscov2infectionandinflammatoryevents |